MaaT03X
Solid Tumors (with ICI)
ResearchDiscovery
Key Facts
About MaaT Pharma
MaaT Pharma is a clinical-stage company focused on leveraging the gut microbiome to improve survival in cancer patients. Its core strategy is built on a differentiated 'full ecosystem' therapeutic platform, with lead candidate MaaT013 in Phase 3 for acute Graft-versus-Host Disease (aGvHD). The company has established integrated R&D and cGMP manufacturing capabilities and is publicly traded on Euronext Paris to fund its ambitious late-stage clinical programs.
View full company profile